Orthofix Medical Inc. Common Stock (DE) (OFIX) Stock
Key stats
- Market cap
- $292.58M
- Price / Earnings ratio
- -6.4x
- EPS (TTM)
- -$1.11
- Volume
- Loading
- 52-week high
- $16.42
- 52-week low
- $6.52
Source: third-party data provider, as of November 13, 2026
Compare with OFIX
Recent news

Orthofix to Report Third Quarter 2026 Financial Results
Orthofix to Report Third Quarter 2026 Financial Results
OFIX

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
OFIX

Orthofix Medical Q2 Earnings Call Highlights
Orthofix Medical Q2 Earnings Call Highlights
OFIX

Bet on 5 Top-Ranked Stocks With Rising P/E
Bet on 5 Top-Ranked Stocks With Rising P/E
OFIX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 31.24
- MACD 12/26/9
- -0.48
- EMA 9 of MACD
- -0.20
- MACD histogram
- -0.28
- SMA 50
- $9.16
- Price below SMA 50
- EMA 50
- $9.26
- Price below EMA 50
- SMA 200
- $10.88
- Price below SMA 200
- EMA 200
- $11.10
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Orthofix to Report Third Quarter 2026 Financial Results
Orthofix to Report Third Quarter 2026 Financial Results
OFIX

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
OFIX

Orthofix Medical Q2 Earnings Call Highlights
Orthofix Medical Q2 Earnings Call Highlights
OFIX

Bet on 5 Top-Ranked Stocks With Rising P/E
Bet on 5 Top-Ranked Stocks With Rising P/E
OFIX

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates
Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates
OFIX

Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
OFIX

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for
OFIX

Wall Street Analysts Think Orthofix (OFIX) Could Surge 33.28%: Read This Before Placing a Bet
Wall Street Analysts Think Orthofix (OFIX) Could Surge 33.28%: Read This Before Placing a Bet
OFIX

Orthofix to Participate in Upcoming Investor Conferences
Orthofix to Participate in Upcoming Investor Conferences
OFIX

Orthofix to Report Second Quarter 2026 Financial Results
Orthofix to Report Second Quarter 2026 Financial Results
OFIX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Orthofix Medical Inc. Common Stock (DE)
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Massimo Calafiore | President, CEO & Director | 1972 |
| Ms. Julie B. Andrews | Chief Financial Officer | 1971 |
| Ms. Aviva McPherron | President of Global Operations & Quality | 1977 |
| Mr. J. Andres Cedron | Chief Legal Officer & Corporate Secretary | 1981 |
| Mr. Patrick Fisher | President of Global Biologics & Limb Reconstruction | 1974 |
| Mr. Geoffrey C. Gillespie | Chief Accounting Officer | — |
| Ms. Julie D. Dewey | Chief Investor Relations & Communications Officer | 1961 |
| Ms. Jill Mason | Chief Compliance & Risk Officer | — |
| Ms. Stephanie Walsh | Chief Human Resources Officer | — |
| Dr. Beau Standish P.Eng., Ph.D. | Chief Enabling Technologies Officer | 1980 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 31.24
- MACD 12/26/9
- -0.48
- EMA 9 of MACD
- -0.20
- MACD histogram
- -0.28
- SMA 50
- $9.16
- Price below SMA 50
- EMA 50
- $9.26
- Price below EMA 50
- SMA 200
- $10.88
- Price below SMA 200
- EMA 200
- $11.10
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.1 | -1.4 | +26.2 | -23.4 | -0.2 | -1.5 | -17.9 |



